Concord Biotech · NSE: CONCORDBIO · BSE: 543960
Q1 FY26 results · Apr–Jun 2025
Concord Biotech reported revenue from operations of ₹203.99 crore (down 5.5% from Q1 FY25) and net profit of ₹44.06 crore (down 26.1% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 203.99 | 215.80 | −5.5% | 429.88 | −52.5% |
| Other income | 13.68 | 10.31 | +32.7% | 9.38 | +45.8% |
| Total income | 217.67 | 226.11 | −3.7% | 439.27 | −50.4% |
| Profit before share of associates & JVs and tax | 57.24 | 78.17 | −26.8% | 185.09 | −69.1% |
| Share of profit/(loss) of associates & JVs | 1.49 | 1.35 | (1.55) | ||
| Net profit for the period | 44.06 | 59.59 | −26.1% | 140.39 | −68.6% |
| EPS, basic (₹) | 4.21 | 5.70 | −26.1% | 13.42 | −68.6% |
| Net margin (%) | 21.6 | 27.6 | 32.7 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 203.99 | 215.80 | −5.5% | 429.88 | −52.5% |
| Other income | 13.68 | 10.31 | +32.7% | 9.38 | +45.8% |
| Total income | 217.67 | 226.11 | −3.7% | 439.27 | −50.4% |
| Profit before tax | 57.24 | 78.17 | −26.8% | 185.09 | −69.1% |
| Net profit for the period | 42.57 | 58.24 | −26.9% | 141.94 | −70.0% |
| EPS, basic (₹) | 4.07 | 5.57 | −26.9% | 13.57 | −70.0% |
| Net margin (%) | 20.9 | 27.0 | 33.0 |
Consolidated
- Filed with BSE
- 08 Aug 2025, 17:05 IST
- Board meeting
- 08 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Aug 2025, 17:05 IST
- Board meeting
- 08 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE